- Report
- August 2023
- 70 Pages
South Korea
From €4348EUR$4,750USD£3,695GBP
- Report
- April 2023
- 110 Pages
Global
From €4348EUR$4,750USD£3,695GBP
- Report
- October 2022
- 70 Pages
Africa
From €4348EUR$4,750USD£3,695GBP
- Report
- August 2020
- 150 Pages
Global
From €3890EUR$4,250USD£3,306GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,096USD£3,079GBP
- Report
- May 2025
- 50 Pages
Global
From €2426EUR$2,650USD£2,062GBP
- Report
- May 2025
- 50 Pages
Global
From €2426EUR$2,650USD£2,062GBP
Sitagliptin is a drug used to treat endocrine and metabolic disorders. It is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which works by increasing the levels of incretin hormones in the body. These hormones help to regulate glucose levels in the blood, and can help to reduce the risk of developing type 2 diabetes. Sitagliptin is usually prescribed in combination with other drugs, such as metformin, to help control blood sugar levels. It is also used to treat other conditions, such as polycystic ovary syndrome and non-alcoholic fatty liver disease.
Sitagliptin is available in both oral and injectable forms, and is generally well tolerated with few side effects. It is a relatively new drug, and is becoming increasingly popular as a treatment for endocrine and metabolic disorders.
Some companies in the Sitagliptin market include Merck & Co., Inc., Novartis AG, and Takeda Pharmaceutical Company Limited. Show Less Read more